SAB Biotherapeutics (SABS) Interest Coverage Ratio Growth (1y) (2022 - 2026)
Powered by 
Analysis
SAB Biotherapeutics (SABS) Interest Coverage Ratio Growth (1y) (2022 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -60.78% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -176.09% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 93.04% |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -25.59% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1,170.12% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -53.46% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 99.48% |
| 10 | SAB Biotherapeutics | 296.68 Mn | 296.68 Mn | - | -147.96% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -147.96% |
| Mar 31, 2026 | -105.82% |
| Dec 31, 2025 | -75.97% |
| Sep 30, 2025 | -102.08% |
| Jun 30, 2025 | -38.80% |
| Mar 31, 2025 | -3.82% |
| Dec 31, 2024 | 41.73% |
| Sep 30, 2024 | -89.77% |
| Jun 30, 2024 | -27.41% |
| Mar 31, 2024 | -86.15% |
| Dec 31, 2023 | -170.40% |
| Sep 30, 2023 | 30.92% |
| Jun 30, 2023 | 6.38% |
| Mar 31, 2023 | 13.97% |
| Dec 31, 2022 | 19.12% |
| Sep 30, 2022 | -117.63% |
| Jun 30, 2022 | -138.00% |
| Mar 31, 2022 | -960.35% |